SA518391864B1 - مشتقات باي بيرازوليل مفيدة لمعالجة أمراض المناعة الذاتية - Google Patents
مشتقات باي بيرازوليل مفيدة لمعالجة أمراض المناعة الذاتيةInfo
- Publication number
- SA518391864B1 SA518391864B1 SA518391864A SA518391864A SA518391864B1 SA 518391864 B1 SA518391864 B1 SA 518391864B1 SA 518391864 A SA518391864 A SA 518391864A SA 518391864 A SA518391864 A SA 518391864A SA 518391864 B1 SA518391864 B1 SA 518391864B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- treatment
- bipyrazolyl
- autoimmune diseases
- derivatives useful
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Abstract
يتعلق الاختراع الحالي بمركبات بالصيغة (I) (I)، حيث تم تعريف R1، Cy وY في هذه الوثيقة، والتي تكون مناسبة لمعالجة أمراض متعلقة بكيناز تيروسين Bruton Bruton's tyrosine kinase (BTK)، وعمليات لتحضير تلك المركبات، والمستحضرات الصيدلانية pharmaceutical preparations التي تحتوي على تلك المركبات، وطرق للاستخدام. شكل 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562268278P | 2015-12-16 | 2015-12-16 | |
US201662431008P | 2016-12-07 | 2016-12-07 | |
PCT/US2016/066799 WO2017106429A2 (en) | 2015-12-16 | 2016-12-15 | Heteroaromatic compounds as btk inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SA518391864B1 true SA518391864B1 (ar) | 2021-12-13 |
Family
ID=58737849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SA518391864A SA518391864B1 (ar) | 2015-12-16 | 2018-06-23 | مشتقات باي بيرازوليل مفيدة لمعالجة أمراض المناعة الذاتية |
Country Status (31)
Country | Link |
---|---|
US (6) | US9975882B2 (ar) |
EP (1) | EP3390390B1 (ar) |
JP (1) | JP6976947B2 (ar) |
KR (1) | KR20180095655A (ar) |
CN (1) | CN108368086B (ar) |
AU (1) | AU2016370743B2 (ar) |
BR (1) | BR112018011969B1 (ar) |
CA (1) | CA3005268C (ar) |
CL (1) | CL2018001569A1 (ar) |
CO (1) | CO2018005954A2 (ar) |
CY (1) | CY1124749T1 (ar) |
DK (1) | DK3390390T3 (ar) |
EA (1) | EA034561B1 (ar) |
ES (1) | ES2897910T3 (ar) |
HK (1) | HK1256795A1 (ar) |
HR (1) | HRP20211845T1 (ar) |
HU (1) | HUE056877T2 (ar) |
IL (1) | IL259281B (ar) |
LT (1) | LT3390390T (ar) |
MX (1) | MX2018007333A (ar) |
MY (1) | MY197440A (ar) |
PE (1) | PE20181074A1 (ar) |
PH (1) | PH12018501248A1 (ar) |
PL (1) | PL3390390T3 (ar) |
PT (1) | PT3390390T (ar) |
RS (1) | RS62525B1 (ar) |
SA (1) | SA518391864B1 (ar) |
SG (1) | SG11201804890TA (ar) |
SI (1) | SI3390390T1 (ar) |
TW (1) | TWI726017B (ar) |
WO (1) | WO2017106429A2 (ar) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014025976A1 (en) | 2012-08-10 | 2014-02-13 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
PE20220507A1 (es) | 2015-12-16 | 2022-04-07 | Loxo Oncology Inc | Compuestos utiles como inhibidores de cinasa |
CN108368086B (zh) * | 2015-12-16 | 2021-01-08 | 勃林格殷格翰国际有限公司 | 可用于治疗自身免疫疾病的二吡唑基衍生物 |
WO2017123695A1 (en) | 2016-01-13 | 2017-07-20 | Boehringer Ingelheim International Gmbh | Isoquinolones as btk inhibitors |
CN110944999A (zh) * | 2017-08-01 | 2020-03-31 | 勃林格殷格翰国际有限公司 | 中间体化合物和方法 |
CA3108065A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
EP3972603A1 (en) * | 2019-05-23 | 2022-03-30 | Novartis AG | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor |
JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
WO2023110970A1 (en) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Macrocyclic btk inhibitors |
WO2023110936A1 (en) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Reversible macrocyclic kinase inhibitors |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9608435D0 (en) | 1996-04-24 | 1996-06-26 | Celltech Therapeutics Ltd | Chemical compounds |
EP1196390A2 (en) * | 2000-02-05 | 2002-04-17 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
ES2264734T3 (es) | 2001-08-13 | 2007-01-16 | Janssen Pharmaceutica N.V. | Derivados de tiazolilo 2,4,5-trisustituidos y su actividad antiinflamatoria. |
JP2006515828A (ja) | 2001-09-27 | 2006-06-08 | スミスクライン・ビーチャム・コーポレイション | 化学化合物 |
FR2881426B1 (fr) | 2005-02-03 | 2007-03-30 | Aventis Pharma Sa | Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation |
ES2376765T3 (es) | 2006-04-11 | 2012-03-16 | Vertex Pharmaceuticals, Inc. | Tiazoles, imidazoles y pirazoles útiles como inhibidores de proteína quinasas |
BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
MX2009010284A (es) | 2007-03-28 | 2010-01-29 | Pharmacyclics Inc | Inhibidores de la tirosina-cinasa de bruton. |
NZ590567A (en) | 2008-07-29 | 2012-06-29 | Univ Liege | A genetic marker test for brachyspina ( based on snp on bovine chromosome 21) and fertility in cattle |
GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
CN102395585A (zh) | 2009-01-30 | 2012-03-28 | 米伦纽姆医药公司 | 杂芳基化合物和其作为pi3k抑制剂的用途 |
US8907098B2 (en) | 2009-12-17 | 2014-12-09 | Merck Patent Gmbh | Inhibitors of sphingosine kinase |
RS55184B1 (sr) | 2010-05-31 | 2017-01-31 | Ono Pharmaceutical Co | Derivat purinona kao inhibitor btk kinaze |
JP2013533318A (ja) | 2010-08-11 | 2013-08-22 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | ヘテロアリールおよびその使用 |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
JP5985658B2 (ja) * | 2012-01-31 | 2016-09-06 | ナンジン アルゲン ファルマ カンパニー リミテッドNanjing Allgen Pharma Co. Ltd. | ブルトンチロシンキナーゼ阻害薬としての環状分子 |
WO2014025976A1 (en) | 2012-08-10 | 2014-02-13 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
ES2625944T3 (es) | 2012-11-02 | 2017-07-21 | Pfizer Inc. | Inhibidores de tirosina cinasa de Bruton |
CN103848810A (zh) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
WO2014151620A1 (en) * | 2013-03-14 | 2014-09-25 | Boehringer Ingelheim International Gmbh | 5-thiazolecarboxamide dervatives and their use as btk inhibitors |
EP3099674B1 (en) | 2014-01-29 | 2018-10-24 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as btk inhibitors |
CN108368086B (zh) * | 2015-12-16 | 2021-01-08 | 勃林格殷格翰国际有限公司 | 可用于治疗自身免疫疾病的二吡唑基衍生物 |
-
2016
- 2016-12-15 CN CN201680072250.3A patent/CN108368086B/zh active Active
- 2016-12-15 TW TW105141510A patent/TWI726017B/zh active
- 2016-12-15 JP JP2018531127A patent/JP6976947B2/ja active Active
- 2016-12-15 CA CA3005268A patent/CA3005268C/en active Active
- 2016-12-15 PT PT168673788T patent/PT3390390T/pt unknown
- 2016-12-15 SI SI201631382T patent/SI3390390T1/sl unknown
- 2016-12-15 BR BR112018011969-5A patent/BR112018011969B1/pt active IP Right Grant
- 2016-12-15 HR HRP20211845TT patent/HRP20211845T1/hr unknown
- 2016-12-15 MX MX2018007333A patent/MX2018007333A/es active IP Right Grant
- 2016-12-15 LT LTEPPCT/US2016/066799T patent/LT3390390T/lt unknown
- 2016-12-15 DK DK16867378.8T patent/DK3390390T3/da active
- 2016-12-15 MY MYPI2018000892A patent/MY197440A/en unknown
- 2016-12-15 AU AU2016370743A patent/AU2016370743B2/en active Active
- 2016-12-15 PL PL16867378T patent/PL3390390T3/pl unknown
- 2016-12-15 KR KR1020187020450A patent/KR20180095655A/ko active IP Right Grant
- 2016-12-15 EP EP16867378.8A patent/EP3390390B1/en active Active
- 2016-12-15 PE PE2018001111A patent/PE20181074A1/es unknown
- 2016-12-15 US US15/379,745 patent/US9975882B2/en active Active
- 2016-12-15 HU HUE16867378A patent/HUE056877T2/hu unknown
- 2016-12-15 ES ES16867378T patent/ES2897910T3/es active Active
- 2016-12-15 SG SG11201804890TA patent/SG11201804890TA/en unknown
- 2016-12-15 WO PCT/US2016/066799 patent/WO2017106429A2/en active Application Filing
- 2016-12-15 RS RS20211356A patent/RS62525B1/sr unknown
- 2016-12-15 EA EA201891399A patent/EA034561B1/ru not_active IP Right Cessation
-
2017
- 2017-10-12 US US15/782,214 patent/US20180030037A1/en not_active Abandoned
-
2018
- 2018-04-09 US US15/947,978 patent/US20180222893A1/en not_active Abandoned
- 2018-05-10 IL IL259281A patent/IL259281B/en active IP Right Grant
- 2018-06-12 CO CONC2018/0005954A patent/CO2018005954A2/es unknown
- 2018-06-13 PH PH12018501248A patent/PH12018501248A1/en unknown
- 2018-06-13 CL CL2018001569A patent/CL2018001569A1/es unknown
- 2018-06-23 SA SA518391864A patent/SA518391864B1/ar unknown
- 2018-09-21 US US16/137,790 patent/US20190092759A1/en not_active Abandoned
- 2018-12-11 HK HK18115878.5A patent/HK1256795A1/zh unknown
-
2019
- 2019-08-29 US US16/555,205 patent/US20200055843A1/en not_active Abandoned
-
2020
- 2020-07-23 US US16/936,821 patent/US20210009567A1/en not_active Abandoned
-
2021
- 2021-11-24 CY CY20211101015T patent/CY1124749T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA518391864B1 (ar) | مشتقات باي بيرازوليل مفيدة لمعالجة أمراض المناعة الذاتية | |
MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
PH12016501192B1 (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
TR201819138T4 (tr) | FGFR Kinaz Modülatörleri Olarak Faydalı Kinoksalin Türevleri | |
TW201613886A (en) | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones | |
EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
EA201790519A1 (ru) | Терапевтические соединения в качестве ингибиторов рецептора орексина-1 | |
PH12019502693A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
TW201613864A (en) | Novel compounds | |
MX2017007377A (es) | Compuestos organicos. | |
PH12017500853A1 (en) | Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases | |
PH12021551280A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
MX2021006489A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
PH12021550269A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
PH12016501613B1 (en) | Pyrazines modulators of gpr6 | |
EA201692216A1 (ru) | Пирролидиновые модуляторы gpr40 для лечения заболеваний, таких как диабет | |
MX2019002017A (es) | Derivados de sofosbuvir para el tratamiento de la hepatitis c. | |
MX2021006490A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
MX2017007380A (es) | Compuestos organicos. |